Rhythm Pharmaceuticals, Inc. (RYTM) is set to face a pivotal FDA decision tomorrow, March 20, 2026, on its sNDA to expand the label of Imcivree to include treatment of acquired hypothalamic obesity.
Imcivree (setmelanotide) is already FDA-approved for chronic weight management in adults and children aged two years and older with certain rare genetic forms of obesity, including Bardet-Biedl syndrome (BBS), POMC, PCSK1 or LEPR deficiency.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.